ABSTRACT NUMBER: ESOC2026A2001 RISK FACTORS FOR CLOPIDOGREL RESISTANCE IN PATIENTS WITH ISCHEMIC STROKE OR TIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF SIXTY-FIVE PRIMARY STUDIES
Yusof M Omar, Abdullah Almarfadi, Fawaz K Alfahmi, Jamal Ahmad, Omar Salloum, Abdelrahman Abdelhameed Hashem, Moamen Samy Syaj, Omnia Samy El-Sayed · 2026
Read ABSTRACT NUMBER: ESOC2026A2001 RISK FACTORS FOR CLOPIDOGREL RESISTANCE IN PATIENTS WITH ISCHEMIC STROKE OR TIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF SIXTY-FIVE PRIMARY STUDIES by Yusof M Omar, Abdullah Almarfadi, Fawaz K Alfahmi, Jamal Ahmad, Omar Salloum, Abdelrahman Abdelhameed Hashem, Moamen Samy Syaj, Omnia Samy El-Sayed (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13145810.txt.
Description
Yusof M Omar and co-authors present a 2026 conference review of what drives resistance to a common clot drug after stroke or a warning event. The drug fails in many patients, who then face repeat events. Past reports on its risk factors clash, so the team pooled the field.
Sixty-five studies with near twelve thousand patients fed the review. Resistant patients ran slightly older, with higher blood sugar marks and cholesterol, and lower blood counts. Sugar disease raised the odds of resistance. Being male, smoking now, and one gene form each tied to lower odds of the drug failing. The authors call resistance a mixed product of body state, habits, and genes.
Catalog record
| CREATOR | Yusof M Omar, Abdullah Almarfadi, Fawaz K Alfahmi, Jamal Ahmad, Omar Salloum, Abdelrahman Abdelhameed Hashem, Moamen Samy Syaj, Omnia Samy El-Sayed |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |